Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Ionis Pharmaceuticals, Inc.

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampIonis Pharmaceuticals, Inc.Summit Therapeutics Inc.
Wednesday, January 1, 2014201400006795238
Thursday, January 1, 2015371730007454247
Friday, January 1, 20164861600010345862
Sunday, January 1, 201710848800016984203
Monday, January 1, 201824462200016187290
Tuesday, January 1, 20192870000009299233.54
Wednesday, January 1, 202035400000019232000
Friday, January 1, 202118600000023611000
Saturday, January 1, 202215100000026700000
Sunday, January 1, 202323260000028215000
Monday, January 1, 2024267474000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Summit Therapeutics Inc. and Ionis Pharmaceuticals, Inc. from 2014 to 2023. Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics, has seen its SG&A expenses grow significantly, peaking in 2020 with a 1,660% increase from 2014. Meanwhile, Summit Therapeutics, known for its innovative antibiotic solutions, has maintained a more modest growth, with expenses increasing by approximately 315% over the same period. This disparity highlights Ionis's aggressive expansion and investment in its operations compared to Summit's more conservative approach. As the biotech industry continues to evolve, understanding these financial strategies provides valuable insights into each company's market positioning and future potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025